Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Myriad Genetics' BRACAnalysis CDx for determining which HER2-negative, metastatic breast cancer patients have inherited BRCA1 and BRCA2 genetic mutations and therefore may benefit from treatment with Pfizer's Talzenna (talazoparib).

The companion diagnostic approval accompanied the regulatory approval of Pfizer's PARP inhibitor Talzenna. Talzenna is indicated as a treatment for advanced or metastatic breast cancer patients who have BRCA mutations as determined by an FDA-approved companion diagnostic.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.